Is Biogen Inc halal to invest in?

As of August 2026, Biogen Inc BIIB.VI is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Biogen Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Biogen Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Biogen Inc?

Muslim investors may consider investing in Biogen Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Biogen Inc classified as HALAL?

Musaffa determines the Shariah status of Biogen Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Biogen Inc updated?

The Shariah compliance status of Biogen Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Biogen Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Biogen Inc?

You can check the latest Shariah compliance status of Biogen Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Biogen Inc BIIB.VI

Last Updated: Aug 13, 12:00 AM·WBAG

BIIB.VI Shariah Compliance

Screening Methodology: AAOIFI

As of August 2026, Biogen Inc is classified as halal.

HALAL

Report Source: undefined Quarter Report

Biogen Inc. Stock Analysis BIIB.VI

Austria Health Care Large Cap

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).